For the treatment of other groups, it is well established that the effects of CDK4/6 inhibitors reduce the activity of the E2F target DNA methyltransferase 1 and suppress the proliferation of tumour cells and regulatory T cells [45]. Here, CDK4 is linked to neoplasm.